Transgene

Transgene EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Transgene (TNG.PA) as of Oct 8, 2026 is -8.51. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -6.28 — a change of 35.52% (lower).

EV/FCF

-8.51

YoY

35.52%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Transgene is 2024 -8.51 . EV/FCF (Enterprise Value to Free Cash Flow) of Transgene was 2023 -6.28 . It decreases by 35.52% lower compared to the previous year.

The Transgene EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2017
-6.52 EUR
Jan 1, 2018
-8.10 EUR
Jan 1, 2019
-8.52 EUR
Jan 1, 2020
-7.16 EUR
Jan 1, 2021
-7.04 EUR
Jan 1, 2022
-10.07 EUR
Jan 1, 2023
-6.28 EUR
Jan 1, 2024
-8.51 EUR
The Transgene EV/FCF history
YEAREV/FCFYoY
-8.51+35.52%
-6.28-37.67%
-10.07+43.05%
-7.04-1.69%
-7.16-15.98%
-8.52+5.17%
-8.10+24.19%
-6.52-1.15%
-6.60+29.68%
-5.09+42.09%
-3.58—
Access this data via the Eulerpool API

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

EV/FCF (Enterprise Value to Free Cash Flow) of Transgene is -8.51 in 2024.

EV/FCF (Enterprise Value to Free Cash Flow) of Transgene changed from -6.28 to -8.51, representing a 35.52% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Transgene since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Transgene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Transgene

All Key Metrics — Transgene